Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831926 | 0.89 | PDE4B (0.36) | GPR119MAPTLMNANPBWR1MCHR1 | |
| SCHEMBL20832054 | 0.87 | GPR119 (0.44) | SMARCA2SMARCA4PBRM1GPR119MAPT | |
| SCHEMBL20818165 | 0.87 | RXRA (0.34) | LMNAATR | |
| SCHEMBL22749600 | 0.83 | MAPT (0.42) | SMARCA2SMARCA4PBRM1GPR119MAPT | |
| SCHEMBL23462475 | 0.77 | LMNA (0.40) | LMNATHRBNPBWR1MCHR1MEN1 | |
| SCHEMBL23489982 | 0.77 | LMNA (0.40) | LMNATHRBNPBWR1MCHR1MEN1 | |
| SCHEMBL20817776 | 0.76 | RXRA (0.35) | LMNA | |
| SCHEMBL20818573 | 0.75 | CYP4F2 (0.37) | LMNAATR | |
| SCHEMBL20436987 | 0.74 | DDB1 (0.44) | GPR119 | |
| SCHEMBL20818306 | 0.74 | IDH1 (0.37) | GPR119LMNAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435078-B2 | Pyridazinones and methods of use thereof | GFB (ABC), LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | SMARCA2 3392/4885SMARCA4 3400/4885PBRM1 2057/4885 |
| US-12435078-B2 | Pyridazinones and methods of use thereof | PDXK, ATP6V1B1, REN | SMARCA2 3392/4885SMARCA4 3400/4885PBRM1 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.